Full-Time

Clinical Research Associate II

Posted on 9/11/2025

Precision Medicine Group

Precision Medicine Group

201-500 employees

Biomarker-driven clinical development services and consulting

No salary listed

Remote in Germany

Remote

Category
Biology & Biotech (2)
,
Requirements
  • University degree life science/pharmacy/other health related discipline or equivalent experience in a scientific or healthcare discipline or be a licensed health care professional.
  • 2 years or more as a CRA in either a CRO or pharmaceutical/ biotech industry or equivalent, relevant experience and/or demonstrated competencies. Site management or equivalent experience in clinical research
  • Excellent communication and organizational skills are essential. A team player.
  • Evidence of a client focused approach
  • Experience using computerized information systems, electronic spreadsheets, word processing and electronic mail.
  • Ability to travel overnight. Up to 60% travel on average, based on regional requirements. International travel as needed.
  • Fluency in English and for non-English speaking countries the local language of country where position based
Responsibilities
  • Oversees all aspects of study site management to ensure patient safety is protected, quality of data generated by managed sites resulting in consistently low query levels and in acceptable Quality Assurance reports.
  • Provides guidance at the site and project level towards audit readiness standards and supports preparation for audit and required follow-up actions.
  • Updates, tracks and maintains study specific trial management tools/systems, and status reports.
  • If required, manages site start up procedures including the feasibility and recruitment of potential investigators, preparation of EC/IRB submissions, collection and review of regulatory documents, review and adaptation in Patient Informed Consents, notifications to IRB, EC and regulatory authorities, as appropriate, translation of study related documentation, organization of meetings and other tasks as instructed by the Clinical Trial Manager/Project Manager.
  • If required, assists the negotiation of study budgets and the execution of investigator contracts under directions of Site Contract Management department/designee.
  • Verifies the process of obtaining informed consent has been adequately performed and documented for each subject/patient, as required/appropriate. Assesses factors that might affect subject/patient’s safety and clinical data integrity at an investigator/physician site such as protocol deviation/violations and pharmacovigilance issues.
  • Independently conducts all forms of site visits, including pre-study/ qualification, initiation, routine monitoring, and close-out visits, in accordance with the protocol, local laws, ICH-GCP and Precision SOPs. Prepares and submits for review, accurate and timely monitoring reports from all site visits (on-site and remote).
  • Documents activities via confirmation letters, follow-up letters, trip reports, communication logs, and other required project documents as per SOPs, Clinical Monitoring Plan/Site Management Plan and client requirements. Supports subject/patient recruitment, retention and awareness strategies. Enters data into tracking systems as required to track all observations, ongoing status and assigned action items to resolution.
  • Routinely reviews the Investigator Site File (ISF) for accuracy, timeliness and completeness. Reconciles contents of the ISF with the Trial Master File (TMF). Ensures the investigator/physician site is aware of the requirement of archiving essential documents in accordance with local guidelines and regulations.
  • Communicates effectively and proactively with both site personnel and Precision Project and Clinical Trial Management to relay protocol/study issues including any deviations and implements necessary actions in response to those issues.
  • Develops and maintains good working relationship with investigators and study staff, serving as an ambassador to promote Precision high quality and professional image.
  • Performs investigational product (IP) inventory, reconciliation and reviews storage and security. Verifies the IP has been dispensed and administered to subjects/patients according to the protocol. Verifies issues or risks associated with blinded or randomized information related to IP. Applies knowledge of GCP/local regulations and organizational procedures to ensure IP is appropriately (re)labelled, imported and released/returned.
  • Performs data review activities, including remote EDC CRF and patient profiles review, query resolution, and assists data management and clinical data quality personnel to resolve data discrepancies.
  • Identifies and processes Serious Adverse Events according to the procedures defined by the study team. Also demonstrates a full understanding of the SAE reporting process.
  • Identifies site risks and escalates those to Clinical Trial Manager/Project Manager with suggested contingencies. Owns the timely and appropriate resolution of the risk with minimal support from project team.
  • Prepares for and attends Investigator Meetings and/or sponsor face-to-face meetings. Participates in global clinical monitoring/project staff meetings (inclusive of Sponsor representation, as applicable) and attends clinical training sessions according to the project specific requirements.
  • Travels as necessary according to project needs.
  • Performs other duties as assigned by management.
Desired Qualifications
  • Graduate or postgraduate degree
  • Oncology phases preferably in early phases
  • Experience monitoring in rare and complex therapeutic areas
  • Experience monitoring EDC trials and EHR records
  • Experience in biopharma or relevant therapeutic area
  • Relevant site start-up (feasibility, contract negotiations, submissions) experience for the particular country
  • Ability to monitor study sites, with supervision, according to protocol monitoring guidelines, SOPs, GCP and ICH guidelines.
  • Ability to resolve project related problems and prioritizes workload to meet deadlines with minimal support from management.
  • Exhibits self-motivation and is able to work and plan independently as well as in a team environment
  • Understands clinical trials methodology, including a working knowledge of protocols and indications being studied
  • Demonstrates professionalism as evidenced by punctuality, ability to deliver on commitments, an understanding of the service culture and positive interactions with customers and teammates, including good interpersonal skills
  • Collects data of consistently high standard
  • Demonstrated ability to conduct formal presentations to a wide variety of audiences including colleagues, investigative staff, and clients with a high level of proficiency
  • Fluent in English and for non-English speaking countries the local language of country where position based
Precision Medicine Group

Precision Medicine Group

View

Precision Medicine Group is a life sciences services organization that supports pharmaceutical and biotech companies across the full product lifecycle, from preclinical work to post-launch commercialization. Its offerings are delivered through integrated units like Precision for Medicine and Precision Value & Health, including biomarker assays, cell and gene therapy logistics via Project Farma, global clinical trial management, and regulatory and market-access consulting. The company differentiates itself with an end-to-end, biomarker-centric platform that unites scientific discovery, trial execution, regulatory support, and payer-facing strategy under one umbrella. Its goal is to de-risk and accelerate the development and commercialization of targeted therapies, growing through a mix of organic development and strategic acquisitions.

Company Size

201-500

Company Stage

Growth Equity (Venture Capital)

Total Funding

$310.2M

Headquarters

Bethesda, Maryland

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Institute@Precision launched November 2025 positions PMG as biopharma thought leadership hub.
  • 3,500 employees across 35 locations enable geographic diversification in precision medicine markets.
  • 2023 CRO Leadership Awards in all categories affirm expertise for pharma and biotech clients.

What critics are saying

  • Rapid C-suite turnover from Clein to Keegan in October 2024 erodes client trust.
  • Labcorp's April 2024 Fortrea acquisition bundles lab-CRO services, capturing PMG's large pharma clients.
  • Thermo Fisher's 2021 PPD acquisition squeezes PMG's mid-tier positioning with lower-cost scale.

What makes Precision Medicine Group unique

  • Biomarker-driven CRO services integrate Precision for Medicine and Precision AQ across drug lifecycle.
  • Specialty labs in seven global locations deliver rapid biomarker data for advanced therapies.
  • Acquisitions like ApoCell in 2015 and Project Farma in 2020 enhance cell and gene therapy logistics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

Disability Insurance

Parental Leave

Paid Vacation

Paid Sick Leave

Remote Work Options

Performance Bonus

Company News

SYMEX ECONOMICS SA
Nov 10th, 2025
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.

Lir Life Sciences Corp. formerly Blackbird Critical Metals Corp. announces closing of acquisition of Lir Life Sciences Inc. VANCOUVER, BC / ACCESS Newswire / November 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY) (formerly Blackbird Critical Metals Corp.) ("Lir Life Sciences" or the "Company") is pleased to announce, further to its news release dated August 14, 2025, that it has completed the acquisition (the "Transaction") of all of the issued and outstanding shares of Lir Life Sciences Inc. ("Lir Inc."), and that trading in the common shares of the Company resumed on the Canadian Securities Exchange (the "CSE") on November 7, 2025, under the ticker symbol "SKNY". The Company acquired 100% of the issued and outstanding shares of Lir Inc. in consideration for the issuance of 22,312,678 post-consolidated common shares of the Company to the former securityholders of Lir Inc. In connection with the completion of the Acquisition, the Company also issued 379,000 common shares (the "Admin Fee Shares") to The Back Office Inc., an arm's-length third party, as an administrative fee for services rendered in support of the Acquisition. The Admin Fee Shares are subject to a statutory hold period of four months and one day under applicable Canadian securities laws. The Company is pleased to announce that Dr. Edward Mills has been appointed Chief Executive Officer and as a Director of the Company. Dr. Mills is a globally recognized leader in clinical trials and public health, with over 550 peer reviewed publications in top-tier journals such as The New England Journal of Medicine and The Lancet. Over the past two decades, he has led some of the largest and most impactful clinical trials ever conducted, particularly focused on evaluating treatments for diseases affecting low-income populations. His work has earned him multiple prestigious awards in clinical research. Dr. Mills has raised over $1 billion to support clinical research and public health initiatives and is among the most widely published clinical researchers in the world. He holds a PhD in clinical research and two master's degrees. Formerly Chief Executive Officer of Platform Life Sciences and a Senior Scientist at VirX@Stanford, he continues to pioneer breakthrough therapies. He is also a successful entrepreneur, having co-founded and exited several healthcare companies, including MTEK Sciences (acquired by Cytel) and Redwood Outcomes (acquired by Precision Medicine Group). Dr. Mills will lead the Company's vision around the development of therapies intended to provide accessible obesity treatment through transdermal delivery. The Company also welcomes Mr. Harry Nijjar as Chief Financial Officer and Corporate Secretary. Mr. Nijjar is the Managing Director at Malaspina Consultants and a seasoned finance executive with extensive experience in financial reporting, corporate governance, and strategic advisory across a wide range of industries. He serves as Chief Financial Officer for multiple public companies and has held Chief Financial Officer positions with numerous TSX Venture Exchange and CSE listed issuers. Mr. Nijjar earned a Bachelor of Commerce from the Sauder School of Business at the University of British Columbia in 2010 and obtained his CPA, CMA designation in 2012. The Company also welcomes Dr. Mark Dybul as a Director. Dr. Dybul is a Professor in the Department of Medicine at Georgetown University Medical Center where he serves as Chief Strategy Officer of the Center for Global Health Practice and Impact. He is also Chair of the Board of Purpose Africa. Dr. Dybul has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher, and administrator. He was a principal architect of and ultimately led with the rank of Ambassador at the level of an Assistant Secretary of State, the US President's Emergency Plan for AIDS Relief ("PEPFAR"). More recently, he served as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. The Company also welcomes Mr. Kevin May as a Director. Mr. May is an experienced lumber trader with a deep understanding of the North American lumber market, supply chain dynamics, and sustainable forestry practices. With a keen ability to navigate complex trade relationships, he plays a pivotal role in sourcing and distributing high quality timber products to meet the needs of diverse industries. Before transitioning into the lumber trade, Mr. May built a strong foundation in international relations as a cross-cultural communicator in Japan. This experience honed his skills in negotiation, market analysis, and relationship management, the essential qualities that now drive his success in the highly competitive lumber industry. In connection with the Acquisition, and as disclosed by way of news release on October 29, 2025, Lir Inc. completed a non-brokered private placement of 3,050,270 subscription receipts at a price of $0.35 per subscription receipt (the "Concurrent Financing"), for aggregate gross proceeds of $1,067,594.50. Each subscription receipt automatically converted into one common share of Lir Inc. immediately prior to Closing, and such Lir Inc. shares were exchanged for common shares of the Company on closing. Lir Inc. also settled $109,343 of outstanding debt by issuing 312,408 Lir Inc. shares at a deemed price of $0.35 per Lir Inc. share, (the "Debt Conversion") which were exchanged for common shares of the Company on closing. The securities issued in connection with the Concurrent Financing and Debt Conversion are subject to a voluntary hold period of four months from the date from closing. Prior to Closing, on October 31, 2025, the Company effected a change of its corporate name from "Blackbird Critical Metals Corp." to "Lir Life Sciences Corp." (the "Name Change"). For further information regarding the Acquisition, the Concurrent Financing or the Name Change, please see the Listing Statement of the Company dated November 3, 2025, a copy of which is available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca or on the CSE's website. Lir Life Sciences is focused on researching and developing scalable and affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other novel delivery systems that mimic GLP-1, a naturally occurring hormone that helps regulate appetite and blood sugar. These therapies could potentially offer an alternative to injectable drugs. The goal is to improve access, adherence, and cost-efficiency in both developed and emerging markets. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science. Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains statements and information that, to the extent that they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation based on current expectations, estimates, forecasts, projections, beliefs and assumptions made by management of the Company. Forward-looking information is generally identified by words such as "believe", "project", "aim", "expect", "anticipate", "estimate", "intend", "strategy", "future", "opportunity", "plan", "may", "should", "will", "would", and similar expressions and, in this news release, includes statements relating to the commencement of trading of the common shares of the Company, the financial and business prospects of the Company, its assets and other matters. Although the Company believes that the expectations and assumptions on which such forward- looking information are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking information in this news release. The forward-looking information included in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release is made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable laws.

Precision Medicine Group
Sep 15th, 2025
Precision Medicine Group Announces Appointment of Tracey Leahy as Chief People Officer

BETHESDA, MD., September 16, 2025 - Precision Medicine Group (Precision), a leading provider of next-generation drug development, CRO and commercialization services, today announced the appointment of Tracey Leahy as the company's Chief People Officer (CPO), effective immediately.

Contract Pharma
Apr 16th, 2025
Precision Medicine Group Appoints Chief Information and Technology Officer

Precision Medicine Group, a provider of next-generation drug development, CRO and commercialization services, has appointed Eric Hodgins as its Chief Information and Technology Officer, overseeing all the company's technology assets.

PR Newswire
Oct 2nd, 2024
Precision Medicine Group Welcomes Margaret Keegan as CEO

BETHESDA, Md., Oct. 1, 2024 /PRNewswire/ - Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Margaret Keegan as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.

Williston Observer
Sep 12th, 2024
Precision Medicine Group Announces New Chief Financial Officer and Establishes Chief Transformation and Strategy Officer Position

BETHESDA, Md., Sept. 12, 2024 /PRNewswire/ - Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of Karl Deonanan as Chief Financial Officer (CFO), responsible for all finance and accounting functions.

INACTIVE